Glenn M Marshall
Overview
Explore the profile of Glenn M Marshall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
4121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seneviratne J, Ravindrarajah D, Carter D, Zhai V, Lalwani A, Krishan S, et al.
Cancer Med
. 2024 Nov;
13(21):e70082.
PMID: 39501501
Background: The child cancer, neuroblastoma (NB), is characterised by a low incidence of mutations and strong oncogenic embryonal driver signals. Many new targeted epigenetic modifier drugs have failed in human...
2.
Cheung B, Mittra R, Murray J, Wang Q, Seneviratne J, Raipuria M, et al.
Commun Biol
. 2024 Oct;
7(1):1322.
PMID: 39402275
MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders...
3.
Mason N, Cahill H, Diamond Y, McCleary K, Kotecha R, Marshall G, et al.
Ther Adv Hematol
. 2024 Jul;
15:20406207241257901.
PMID: 39050114
Children with Down syndrome (DS) are at increased risk of developing haematological malignancies, in particular acute megakaryoblastic leukaemia and acute lymphoblastic leukaemia. The microenvironment established by abnormal haematopoiesis driven by...
4.
Murray J, Valli E, Milazzo G, Mayoh C, Gifford A, Fletcher J, et al.
Nat Commun
. 2024 Jul;
15(1):5585.
PMID: 38992040
MYCN oncogene amplification is frequently observed in aggressive childhood neuroblastoma. Using an unbiased large-scale mutagenesis screen in neuroblastoma-prone transgenic mice, we identify a single germline point mutation in the transcriptional...
5.
Lau L, Khuong-Quang D, Mayoh C, Wong M, Barahona P, Ajuyah P, et al.
Nat Med
. 2024 Jun;
30(7):1913-1922.
PMID: 38844796
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here...
6.
Holliday H, Yang J, Dodson E, Nikolic I, Kamili A, Wheatley M, et al.
Mol Ther
. 2024 May;
32(6):2031-2033.
PMID: 38759647
No abstract available.
7.
Hassan N, Yi H, Malik B, Gaspard-Boulinc L, Samaraweera S, Casolari D, et al.
Blood
. 2024 Apr;
144(1):84-98.
PMID: 38579286
The overall prognosis of acute myeloid leukemia (AML) remains dismal, largely because of the inability of current therapies to kill leukemia stem cells (LSCs) with intrinsic resistance. Loss of the...
8.
Salib A, Jayatilleke N, Seneviratne J, Mayoh C, De Preter K, Speleman F, et al.
Oncogene
. 2023 Dec;
43(5):363-377.
PMID: 38049564
Many of the pro-tumorigenic functions of the oncogene MYCN are attributed to its regulation of global gene expression programs. Alternative splicing is another important regulator of gene expression and has...
9.
Zhai L, Balachandran A, Larkin R, Seneviratne J, Chung S, Lalwani A, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958555
amplification occurs in approximately 20-30% of neuroblastoma patients and correlates with poor prognosis. The transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the...
10.
Wakefield C, Hetherington K, Robertson E, Donoghoe M, Hunter J, Vetsch J, et al.
Br J Cancer
. 2023 Sep;
129(10):1634-1644.
PMID: 37726477
Background: Paediatric precision oncology aims to match therapeutic agents to driver gene targets. We investigated whether parents and patients regret participation in precision medicine trials, particularly when their hopes are...